Main trial launched to discover GLP-1 profit in dementia

A big-scale trial has been launched, with $100 million in backing, to discover whether or not life-style adjustments coupled with GLP-1 agonists or comparable incretin therapies can scale back the chance of dementia.

The three-year PROTECT-Cog examine, introduced on the 2026 Alzheimer’s Association International Congress (AAIC) in London, UK, in the present day, is drawing on earlier examine outcomes exhibiting that life-style adjustments may help enhance reminiscence, considering, and total cognitive operate.

The US POINTER and LatAm-FINGERS trials confirmed {that a} extremely structured life-style programme of food regimen, train, cardiovascular well being monitoring, and brain-training workouts was simpler than self-guided, versatile adjustments at bettering international cognition scores in adults prone to cognitive decline and dementia.

In US POINTER, the enhancements have been equal to roughly one to 2 years of cognitive benefit, which got here alongside different advantages, together with decreasing frailty and sleep apnoea and bettering blood stress management.

The hope is that including in a GLP-1 agonist or similarly-acting drug – akin to Novo Nordisk’s semaglutide or Eli Lilly’s tirzepatide, used to deal with diabetes and for weight reduction – will improve the impact of the approach to life adjustments.

Various retrospective research have pointed to a protecting impact of GLP-1 agonists in dementia, with some exhibiting enhancements of 40% to 70% in comparison with different medicine used to deal with diabetes, however the brand new examine provides a possibility to check that speculation prospectively.

“PROTECT-Cog builds directly on what we learned from US POINTER and takes the next critical step in prevention science,” stated Dr Maria Carrillo, chief science officer and medical affairs lead on the Alzheimer’s Association, and principal investigator of the brand new examine.

“By testing a combined approach that targets both lifestyle and biology, we have the opportunity to better understand how to meaningfully reduce the risk of cognitive decline before symptoms begin,” she added.

PROTECT-Cog will enrol older adults who’re at elevated threat for cognitive decline and evaluate two structured life-style change programmes – one intensive and the opposite a barely much less inflexible model – with and with out drug remedy.

Earlier this month, a examine printed in The Lancet Healthy Longevity urged that 45% of all instances of dementia are avoidable with life-style adjustments.

UK registry examine launched

Also this week, the UK has launched a nationwide, digital registry of individuals residing with dementia within the hope of utilizing it as a useful resource to seek out new remedies, in line with the Financial Times.

The BARBARA registry – an acronym for Brain Ageing Registry for Biomarkers, Access to trials, Research, and Adoption – will carry collectively 180 present analysis databases or inhabitants well being research so as to enhance entry to scientific trials, stated the report. It is being run as a part of the Dame Barbara Windsor Dementia Goals programme, and is called after the beloved actress who developed Alzheimer’s and died in 2020.

Funding for the venture is being supplied by the UK authorities, philanthropic foundations, and the pharma business.